What is ART-TG ?

The Technological Research Accelerator in Genomic Therapy (ART-TG) is an academic biomedical research laboratory to promote excellence in gene therapy research by advancing innovative products towards clinical trials. ART-TG is one of the key "Accelerators" and "Integrators" of Inserm,

​

What do we provide ?​

A continuum of R&D in cell and gene therapy, including preclinical, clinical and service activities that are certified iso9001.

​

Our expertise on  lentiviral vectors:

We develop lentiviral vector bioproduction processes ranging from R&D activities to the preparation of industrial manufacturing for clinical trials, including analytics.  

​

Genomic and Genome Editing Quality Control Platform:​

ART-TG is hosting the Genomic and Genome Editing Quality Control Platform of the Genother biocluster in collaboration with the laboratories of M. Amendola (UMR_S951) and A. Miccio (Institute Imagine). We aim to support the development of safe Advanced Therapy Medicinal Products (ATMPs) utilizing genome-modifying strategies such as CRISPR-tools or lentiviral vectors. See poster.

​

Partnerships:

Inserm Transfert accompanies the partnerships of ART-TG.

  

Our location: 

Within the Evry Genopole and Université Paris-Saclay campus, south of Paris, France.​​

 

Contact us:

click here for inquiries​

For job opportunities go to our page JOBS

​